Buprenorphine/naloxone - IndiviorAlternative Names: Buprenorphine hemiadipate HCl/naloxone HCl dihydrate; Buprenorphine hemiadipate hydrochloride/naloxone hydrochloride dihydrate; RBP-6300
Latest Information Update: 08 Jun 2016
At a glance
- Originator Reckitt Benckiser Pharmaceuticals
- Developer Indivior
- Class Antidotes; Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Opioid abuse